Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture

Shibata, Minoru; Onozuka, Yasushi; Morizane, Toshio; Koizumi, H.; Kawaguchi, Naomi; Miyakawa, Hiroshi; Kako, Makoto; Mitamura, Keiji

doi:10.1007/s00535-003-1285-6

Cited by 58 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering both PBC and AMA prevalences in the Japanese population, Shibata et al inferred that only 0.73% of the AMA carriers in Japan should suffer from symptomatic PBC. (23) These data, which are in keeping with ours, point out that AMArelated conditions are a wide, poorly known area from which PBC, as the tip of the iceberg, would just be the known side.…”

Section: Discussionsupporting

confidence: 85%

“…(17)(18)(19) Systematic screening of blood donors and healthy subjects shows AMA-positive results in 0.07%-9.9% of individuals, depending on the techniques and diagnostic thresholds used, as well as on the type, age, and sex structures of the populations screened. (20)(21)(22)(23)(24) The relatively high rate (2.5% of all tests) of AMA positivity observed in our study may be related to the equivocal nature of low titers of AMAs detected by IF, but is more likely to be driven by the population concerned. The proportion of positive results is typically bigger in the female population above 40 years.…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

et al. 2017

View full text Add to dashboard Cite

The prevalence, clinical characteristics, and outcomes of patients with antimitochondrial antibodies (AMAs), but no clinical evidence of primary biliary cholangitis (PBC), are largely unknown. A prospective study of AMA incidence was conducted through a nation-wide network of 63 French immunology laboratories. Clinical data from 720 of 1,318 AMApositive patients identified in 1 year were collected. Patients were categorized as either newly diagnosed with PBC (n 5 275), previously diagnosed with PBC (n 5 216), or with nonestablished diagnosis of PBC (n 5 229). The latter group was specifically evaluated. Follow-up data were collected for up to 7 years after detection of AMAs. Prevalence of AMApositive patients without evidence of PBC was 16.1 per 100,000. These patients had the following characteristics: 78% female; median age 58 years; median AMA titer 1:160; extrahepatic autoimmune disorders 46%; normal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the upper limit of normal 13%; and cirrhosis 6%. Compared to those newly diagnosed with PBC, the patients were slightly younger, had lower AMA titers, and lower sex-ratio imbalance. Among the patients with normal ALP and no evidence of cirrhosis, the 5-year incidence rate of PBC was 16%. Whereas no patients died from PBC, the 5-year survival rate was 75%, as compared to 90% in a control, standardized population matched for age and sex (P < 0.05). Conclusion: Nearly half of the newly detected AMAs in clinical practice does not lead to a diagnosis of PBC. PBC is unrecognized in 13% of those cases. Only 1 in 6 patients with AMAs and normal ALP will develop PBC after 5 years. The mortality of AMA-positive patients without PBC is increased irrespective of the risk of PBC development. (HEPATOLOGY 2017;65:152-163).

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 69%

Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Others have reported the prevalence of AMAs in normal populations to be as high as 0.6%. 28,29 Nevertheless, these studies did not assess the prevalence of AMAs in healthy controls matched for age and sex to a cohort of PBC patients. In another study, the prevalence of AMAs among corporate workers undergoing annual health check-ups was 0.44% (5 out of 1145); however, when the data were stratified by sex, the AMA prevalence in females was 0.91%, and all 5 of the affected individuals were females older than 40 years of age.…”

Section: Discussionmentioning

confidence: 99%

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…However, the AMA-positive rate of healthy people in Japan was 0.64% (11/1714) (12). In addition, enzyme-linked immunosorbent assay (ELISA)/ western blot tests indicated that 4.6% (14/302) of the entire spectrum of collagen diseases and 4.2% (3/71) of SLE cases were AMA-positive, while the total AMA-positive rate of collagen diseases (excluding cases diagnosed as PBC) was 3.0% (9/297) (13).…”

Section: Discussionmentioning

confidence: 99%

A Case of Primary Biliary Cirrhosis which Developed Eight Years after Diagnosis of Systemic Lupus Erythematosus

Shizuma

Kuroda

2011

Intern. Med.

View full text Add to dashboard Cite

A 29-year-old Japanese female was diagnosed with systemic lupus erythematosus (SLE) at the age of 21 and went into remission after administration of prednisolone. Although no liver dysfunction had been observed upon diagnosis of SLE or during follow-up, an increase of hepatobiliary enzyme levels was seen eight years after the diagnosis of SLE. Antimitochondrial antibodies were positive. Cell infiltration around intrahepatic bile ducts and granuloma formation were observed in the liver. Therefore, she was diagnosed with primary biliary cirrhosis (PBC). Administration of ursodeoxycholic acid resulted in normalization of hepatobiliary enzyme levels. Development of PBC after SLE is extremely rare.

show abstract

Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture

Abstract: AMA is not a rare antibody in the general population, but few people develop recognizable PBC even if they have AMA.

Cited by 58 publications

References 22 publications

Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

A Case of Primary Biliary Cirrhosis which Developed Eight Years after Diagnosis of Systemic Lupus Erythematosus

Contact Info

Product

Resources

About